Skip to content
10-K

Annual Report

ORAMED PHARMACEUTICALS INC. ORMP

0001213900-26-034835

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 26, 2026 40.45M sh
Shares Diluted FY 2025 · Dec 31, 2025 42.42M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 40.85M sh
Stock Repurchased FY 2025 · Dec 31, 2025 $4.74M
Stock Repurchased FY 2025 · Dec 31, 2024 $2.48M
Capex FY 2025 · Dec 31, 2025 $9K
Capex FY 2025 · Dec 31, 2024 $18K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$9.15M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$8.41M
Cash And Equivalents FY 2025 · Dec 31, 2025 $45.95M
Cash And Equivalents FY 2025 · Dec 31, 2024 $54.42M
Stockholders Equity FY 2025 · Dec 31, 2025 $199.74M
Stockholders Equity FY 2025 · Dec 31, 2024 $146.27M
Current Liabilities FY 2025 · Dec 31, 2025 $19.09M
Current Liabilities FY 2025 · Dec 31, 2024 $5.69M
Current Assets FY 2025 · Dec 31, 2025 $133.27M
Current Assets FY 2025 · Dec 31, 2024 $143.22M
Total Assets FY 2025 · Dec 31, 2025 $230.86M
Total Assets FY 2025 · Dec 31, 2024 $155.28M
Eps Diluted FY 2025 · Dec 31, 2025 $1.50
Eps Diluted FY 2025 · Dec 31, 2024 −$0.48
Eps Basic FY 2025 · Dec 31, 2025 $1.53
Eps Basic FY 2025 · Dec 31, 2024 −$0.48
Sga Expense FY 2025 · Dec 31, 2025 $8.72M
Sga Expense FY 2025 · Dec 31, 2024 $6.46M
Rd Expense FY 2025 · Dec 31, 2025 $6.38M
Rd Expense FY 2025 · Dec 31, 2024 $6.32M
Net Income FY 2025 · Dec 31, 2025 $64.05M
Net Income restated FY 2025 · Dec 31, 2024 −$19.06M
Operating Income FY 2025 · Dec 31, 2025 −$15.09M
Operating Income FY 2025 · Dec 31, 2024 −$12.78M
Gross Profit FY 2025 · Dec 31, 2025 $13K
Cost Of Revenue FY 2025 · Dec 31, 2025 $1.99M
Revenue FY 2025 · Dec 31, 2025 $2M
Short Term Debt FY 2025 · Aug 8, 2023 $99.55M